The Remedy Room — Legislation
Legislation We Are Watching
Three core bills and two emerging protections. S.3829 punishes the private-equity looters. S.3822 breaks up the structure. H.R. 6852 establishes the clinical right. The Speak FREE Act shields physicians who speak up. The Healthcare is Human Act stabilizes the workforce they're burning out. None alone closes the loop — but together, they form the first coherent legislative architecture for dismantling the Wrongful Denial Echo Chamber.
Bills
- The Legislative Architecture — How These Bills Work Together
- S.3829 — Corporate Crimes Against Healthcare Act
- S.3822 — Break Up Big Medicine Act
- H.R. 6852 — Advanced Wound Care and Regenerative Medicine Access and Reform Act
- Speak FREE Act — Physician Whistleblower Protection Emerging · Dr. Potter
- Healthcare is Human Act — Healthcare Worker Tax Credit May 2026 Rally · FIGS
The Legislative Architecture
The Wrongful Denial Echo Chamber is not a single problem - it is an interlocking system of failures. Dismantling it requires interlocking solutions. Below is the complete framework, with each piece of legislation named, its function explained, and its relationship to the others.
S.3829 is the sword.
Criminal and civil penalties for executives whose decisions cause patient harm. Unjust enrichment clawbacks. The force of law aimed at the corporation.
The Clinical Integrity Amendment is the shield.
Mandatory State Medical Board referral when an IRE overturn proves Prior Knowledge OmissionPrior Knowledge OmissionA denial issued without referencing documented clinical evidence already present in the patient's medical record that establishes medical necessity.. The personal accountability that S.3829 doesn't reach — stripping the license from the physician who pulled the trigger.
The Buffer Fund is the refuge.
Capitalized by the Amendment's 500% clawback penalties, it provisionally covers denied care during appeal — so patients are not forced to survive the delay while their condition deteriorates. The insurer funds the safety net their denials necessitate.
The Department of Recovery is the courthouse.
A federally-staffed Recovery Coordination Office to absorb IRE overflow, aggregate pattern data that converts individual fraud into prosecutable systemic fraud, and administer the mandatory board reporting pipeline the Amendment requires.
H.R. 6852 is the clinical floor.
It establishes that FDA-approved wound care treatments are covered Medicare benefits. Without it, the enforcement mechanisms above have no clinical standard to enforce. Without S.3829 and the Amendment, H.R. 6852 is a payment rule insurers can still delay and deny around.
§ 6 is the endowment.
The Buffer Fund's long-term sustainability architecture — industry-funded seed capitalization, an endowment layer that generates perpetual yield, and dynamic multiplier scaling tied to the Department of Recovery's annual data. When fraud falls, the fund doesn't collapse. It proves the reform worked.
The Speak Free Act is the shield for physicians.
Born from Dr. Potter's cease-and-desist experience. A federal anti-SLAPP mechanism that protects healthcare workers from institutional retaliation when they speak truthfully about the state of the system. The architecture can only work if the physicians inside it can speak without being silenced. Dr. Potter's page →
S.3829 — Corporate Crimes Against Healthcare Act
Sponsors: Sen. Elizabeth Warren (for herself, Sen. Blumenthal, Sen. Markey, Sen. Merkley, and Sen. Welch)
The Corporate Crimes Against Healthcare Act targets the executives and corporate structures that profit from patient harm. It creates the enforcement mechanism that makes wrongful denial a crime with real consequences — not just a line item in a settlement.
- Unjust Enrichment Clawback: If a healthcare company experiences a "triggering event" — patient harm, bankruptcyBankruptcyPersonal financial insolvency. Medical debt is the leading cause of personal bankruptcy in the United States., or fraud — the Attorney General or any State AG may claw back all covered compensation received by executives during the preceding or succeeding 10 years.
- Criminal Penalty: Any covered party whose actions contributed to a triggering event that results in the deathDeaththe act of dying; the end of life; the total and permanent cessation of all the vital functions of an organism. or injury of a patient faces 1–6 years imprisonment.
- Civil Penalty: Up to 5 times the amount of any clawback authorized — creating the 500% penalty that capitalizes the Patient Safety Buffer Fund.
- Mandatory Ownership Transparency: Requires specified healthcare entities to annually report mergers, acquisitions, ownership changes, and financial structures — with a $5,000,000 penalty for false or missing reports.
- Moral Injury Study: Requires the HHS Inspector General to evaluate profit-driven practices in healthcare delivery and report to Congress — including prior authorizationPrior AuthorizationA health-insurance process that requires your doctor to get advance approval from your plan before it will cover a specific service, procedure, or drug. abuse, upcoding, AI-driven denials, and insurers' efforts to evade state corporate practice of medicine laws.
The gap S.3829 leaves open: S.3829 punishes the corporation and its executive leadership. It does not reach the individual physician who signs the denial letter — the medical director who excludes qualifying clinical data on procedural pretexts and faces no personal accountability for the harm that follows. That gap is precisely what the Clinical Integrity Amendment closes.
The cases the Amendment would have resolved → Room I
The Ballad Health lawsuit, the Lokken estate class action, the Senate investigation — documented in The Problem Room.
Legal Challenges & Lawsuits →S.3822 — Break Up Big Medicine Act
Sponsors: Sen. Elizabeth Warren and Sen. Josh Hawley — one of the most politically unlikely alliances in recent legislative history, united by what the bill's findings call "an unprecedented wave of consolidation."
The fact that Warren and Hawley are co-sponsors of the same healthcare bill tells you something important: the structural corruption of vertical integrationVertical IntegrationA corporate structure in which a single entity owns multiple layers of the healthcare delivery chain — insurer, pharmacy benefit manager, pharmacy, and physician group — creating s… in healthcare is not a partisan issue. It is a market capture issue. The left sees patient exploitation. The right sees monopoly. Both are correct. The bill exists because both diagnoses point to the same cure.
What It Does
The Break Up Big Medicine Act makes it unlawful for any person to simultaneously own or control both a healthcare provider (or management services organization) and an insurance company, pharmacy benefit managerPBM — Pharmacy Benefit ManagerA Pharmacy Benefit Manager (PBM) is the intermediary that administers prescription-drug benefits for health plans and employers — deciding which drugs a plan covers, negotiating re…, or prescription drug wholesaler. Companies in violation have one year to divest.
- Structural Separation: Prohibits common ownership of insurers or PBMs with medical providers. Prohibits common ownership of drug wholesalers with medical providers. The vertical integration that created UHG's empire — insurer + PBM + physician employer + data infrastructure — becomes illegal.
- Hard Divestment Deadline: One year from enactment. Non-compliance triggers an automatic 10% monthly profit escrow, held until divestment occurs. If divestment still doesn't happen, a court-appointed trustee executes the sale.
- Private Right of Action: Individual patients harmed by violations can sue directly — and may recover treble damages plus attorney's fees. This is not a waiting-for-the-government mechanism. Patients can be the enforcement arm.
- FTC + DOJ Joint Enforcement: Both agencies have concurrent jurisdiction to bring civil actions. State attorneys general can also sue as parens patriae on behalf of state residents.
- Disgorgement: Courts may order companies to disgorge all revenue received from entities subject to divestment during the period of violation — not just fines, but stripping the profit from the illegal structure retroactively.
- Quarterly Congressional Reporting: The FTC and DOJ must submit quarterly compliance reports to Congress — creating an ongoing public accountability mechanism.
- Future Blocking Authority: FTC and DOJ gain explicit authority to block any future action that would recreate the prohibited conflicts of interest — closing the re-acquisition loophole.
Congressional Findings (from the Bill Text)
- As of 2023, one conglomerate controls approximately 10% of all American physicians — the single largest employer of physicians in the nation.
- More than three-quarters of all American doctors are now employed by corporate entities.
- The 3 largest PBMs process nearly 80% of all prescription drug claims.
- The 3 largest drug wholesalers control 98% of the U.S. drug distribution market.
- The FTC has found that vertically integrated PBMs have both the ability and incentive to steer business to their own affiliated pharmacies, reducing competition and increasing drug costs.
- Private insurers use employed physicians to intensively document enrollees' medical conditions — generating inflated payments from the Federal government without improving care quality. (The upcoding mechanism, confirmed in the bill's own findings.)
The market conditions S.3822 addresses → Room I
Mayo ClinicMayo ClinicA nonprofit academic medical center with campuses in Minnesota, Arizona, and Florida. Consistently ranked #1 in the U.S. News hospital rankings. exits. LVHN patients displaced. Optum reshuffling. The documented consequences of vertical integration.
Market Power & Hospital Conflicts →⚠️ S.3822 Needs One More Amendment
The Lewin Problem — UHG Subsidiary Designs CMS Policy
S.3822 breaks up the market-facing vertical: insurer + physician + pharmacy. It misses the policy-facing vertical. The Lewin Group — owned by UHG through Optum and OptumServe — is the primary CMS strategic partner and technical contractor. They design the payment models, implement the programs, and evaluate whether they're working. The insurer's subsidiary writes the rules the insurer must follow.
The same structural logic that requires divestiture of pharmacies and clinics requires a conflict-of-interest firewall for federal policy contractors. Editorial independence claims do not sever the conflict. This page documents the ownership chain, the role, and the specific amendment language.
H.R. 6852 — Advanced Wound Care and Regenerative Medicine Access and Reform Act
Sponsor: Rep. Evans of Colorado
Why This Bill Is Personal
ApligrafApligrafAn FDA-approved living cell therapy and bioengineered skin substitute used in chronic wound care, including diabetic foot ulcers and venous leg ulcers. — an FDA-approved skin substitute product (PMA P950032S016, cleared 2000) — was denied by UnitedHealthcareUnited HealthcareThe largest health insurer in the United States by revenue. UnitedHealth Group operates two primary business segments: UnitedHealthcare (health insurance) and Optum (pharmacy care… for 17 months while non-healing wounds progressed to bone demineralization described as "cuttable with a scalpel." When Apligraf was finally approved, it closed those wounds in two weeks. H.R. 6852 directly addresses the payment and coverage framework for products like Apligraf under Medicare. The Denial on Trial framework names this bill explicitly: H.R. 6852 addresses the clinical harm. The Clinical Integrity Amendment and S.3829 provide the enforcement mechanism that gives it teeth.
📋 What the FDAFDAThe U.S. Food and Drug Administration (FDA) decides whether drugs, biologics, and medical devices are safe and effective enough to be sold. Said — Starting in 1995
The following facts are drawn directly from the FDA's Summary of Safety and Effectiveness Data for Apligraf® (PMA P950032, Supplement S016). This is not advocacy. This is the federal regulatory record.
Aug 7, 1995
FDA authorized expedited review based on Apligraf's potential to provide "a clinically important advance over existing alternatives" for neuropathic diabetic foot ulcers. The urgency was recognized 25 years before UHC's denial.
May 22, 1998
FDA approved Apligraf for venous leg ulcers — skin ulcers due to venous insufficiency of greater than 1 month duration that have not adequately responded to conventional therapy. Exactly the indicated use UHC denied.
June 20, 2000
FDA approved Apligraf for diabetic foot ulcers following a prospective, randomized, multi-center controlled clinical trial. Full federal approval issued. Standard of care established.
2018–2019
UnitedHealthcare denied Apligraf for 17 months — 18–21 years after federal approval — while wounds progressed to bone demineralization. When finally approved, the wounds closed in two weeks.
The Clinical Trial Data UHC Ignored
The FDA's pivotal trial (Protocol 95-DUS-001, n=208 patients) demonstrated results confirmed and refined by the manufacturer's ongoing real-world evidence program:
- 56.3% wound closure for Apligraf patients vs 37.5% for control at 12 weeks (p=0.0082)
- Median time to 50% wound closure: 65 days for Apligraf vs 90 days for control (p=0.0026)
- Amputation incidence at 6 months: 6.3% vs 15.6% for control (p=0.028) — Apligraf reduces amputation risk by roughly 60%
- Osteomyelitis incidence at 6 months: 2.7% vs 10.4% for control (p=0.04) — Apligraf reduces bone infection risk by roughly 75%
- No immune rejection observed in any patient. No antibody responses against bovine collagen or human cell components.
Note: The 2000 FDA approval data has since been further validated by the manufacturer's real-world evidence program using large-scale EMR databases. The efficacy profile has strengthened, not weakened, with 25 years of post-market use. The case against the denial gets stronger over time, not weaker.
UHC denied a treatment the FDA recognized as a "clinically important advance" in 1995, approved in 1998 and 2000, that reduces amputation risk by 60% and bone infection risk by 75% in clinical trials — citing it as "not medically necessary" for 17 months. The patient subsequently developed osteomyelitis severe enough that bone was described as "cuttable with a scalpel." The treatment was proven to prevent that exact outcome. When it was finally approved, wounds closed in two weeks.
What It Does
H.R. 6852 reforms how Medicare covers and pays for skin substitute products — cellular, tissue, biological, or synthetic materials applied to wounds and intended to remain in the wound bed. This includes advanced wound treatments like Apligraf that have been FDA-cleared and standard-of-care for decades but remain subject to arbitrary insurance denial and delayed access.
- Medicare Coverage Established: Formally adds skin substitute products as a covered Medicare benefit under Section 1861(s)(2) of the Social Security Act — closing the ambiguity that allows insurers to deny FDA-approved wound treatments as "experimental" or "not medically necessary."
- Standardized Payment: Creates a volume-weighted average payment methodology based on 2023 Medicare data, with annual CPI adjustments — replacing the current pricing chaos that enables over- and under-payment alike. Effective January 1, 2026.
- Site-of-Care Parity: Requires equivalent reimbursement for skin substitute products regardless of the care setting — preventing the practice of denying outpatient access to treatments that would be covered in a hospital setting.
- Program Integrity: Identifies the top 3% of skin substitute product billers as "outlier providers" and requires CMS to conduct prepayment review and, where warranted, prior authorization — targeting fraudulent billing on the provider side while protecting legitimate patient access.
- FDA Streamlining: Directs FDA to conduct a comprehensive review within 18 months of the approval processes for human cellular and tissue allografts — with specific attention to tiered risk frameworks, streamlined application requirements, and reduced duplicative clinical trial burdens. Guidance to be finalized within 36 months.
- Congressional Accountability: Requires a report to the Senate HELP Committee and House Energy & Commerce Committee on findings, recommendations, and estimated patient access impacts.
The Legislative Architecture Connection
H.R. 6852 establishes the clinical right — that FDA-approved wound care treatments are covered Medicare benefits with predictable payment. S.3829 and the Clinical Integrity Amendment establish the enforcement mechanism — that a physician who denies a covered, medically necessary treatment faces license consequences. Without H.R. 6852, the enforcement mechanism has no clinical floor to enforce. Together, they close the loop.
Speak FREE Act — Physician Whistleblower Protection
What It Does
The Speak FREE Act creates a federal mechanism to dismiss Strategic Lawsuits Against Public Participation (SLAPP suits) — legal actions filed by corporations not to win on the merits, but to exhaust and silence critics through litigation cost. In the healthcare context: it would protect physicians, nurses, and healthcare workers from institutional retaliation when they speak truthfully about the state of the system they work in.
The bill's foundation is H.R. 2304 from the 114th Congress — a federal anti-SLAPP mechanism introduced May 13, 2015. The structure is directly applicable to situations like Dr. Potter's: a corporation sends a cease-and-desist to a physician who posted accurate clinical documentation, threatening network termination and license consequences unless she retracts. Without a federal SLAPP shield, the physician faces a choice between silence and ruinous legal defense.
The Documented Case That Generated This Bill
In 2024, United Healthcare sent a cease-and-desist letter to Dr. Elisabeth Potter — a plastic and reconstructive surgeon in Austin, TX — demanding she retract documented clinical content and apologize publicly for speaking about prior authorization practices on social media. Dr. Potter refused. She continued.
The Speak FREE Act was written in direct response to this moment. Rep. Lloyd Doggett subsequently wrote to UHC CEO Stephen Hemsley on Dr. Potter's behalf. The bill turns her individual act of refusal into a federal protection for every physician who follows her.
What It Protects
Healthcare workers who speak truthfully about patient safety, denial practices, coverage gaps, or institutional conduct — shielding them from C&D letters, network termination threats, and SLAPP litigation.
Why It's Necessary
The architecture of reform depends on physicians being able to speak. S.3829's enforcement mechanism relies on documented records. Those records only exist if the physicians who document them can't be silenced first.
Status
Emerging legislation. Dr. Potter advocated for it in private Congressional meetings on May 20, 2026 — the day before the 500-physician Capitol Hill march.
Healthcare is Human Act — Healthcare Worker Tax Credit
What It Does
The Healthcare is Human Act provides up to $6,000 per year in tax credits for healthcare workers practicing in designated shortage areas. Co-written by FIGS — the healthcare apparel company that organized the May 21, 2026 Capitol Hill rally — with bipartisan congressional sponsors.
The bill addresses a documented workforce problem: the healthcare system is burning out the physicians and nurses inside it faster than it can train replacements. Financial incentives for shortage-area practice are one documented lever for redistribution. The Lorna Breen Healthcare Provider Protection Act (chronically underfunded at $45M) is the mental health companion to this financial relief bill.
The Capitol Hill Context — May 21, 2026
On May 21, 2026, 500 physicians, nurses, and healthcare workers marched on Capitol Hill under the "Healthcare is Human" banner. FIGS organized and funded the event. Dr. Potter held private bipartisan Congressional meetings the day before. Noah Wyle — actor, The Pitt, whose mother is a nurse of 50 years — headlined the rally. Bernie Sanders and Tim Kaine attended.
Three bills were on the table: the Healthcare is Human Act (tax credit), the Lorna Breen Act (mental health funding), and the Speak FREE Act (whistleblower protection). The Healthcare is Human Act is the bill that gave the rally its name.
What It Addresses
Healthcare worker shortage and burnout. Physicians and nurses leaving shortage areas because the financial and emotional cost of practicing in an under-resourced environment is not matched by compensation.
How It Connects to the Architecture
A reform architecture that punishes private-equity looting (S.3829), closes the denial-accountability gap (the Clinical Integrity Amendment), breaks up vertical integration (S.3822), and establishes clinical rights (H.R. 6852) still fails if there aren't enough physicians to deliver the care. Workforce stabilization is the foundation all other reforms rest on.